The level of PDGFR-mRNA decreased after application of PDGFR inhibitors, indicating that PDGFR is promoting its own expression, ALK-TKI in combination with PDGFR inhibitors reduces lymphoma growth and decreases relapse rates, and is a potential treatment option for patients with drug-resistant lymphoma. The gene discussed is PDGFRB; the disease is lymphoma.